A Study of Zanubrutinib in Patients With ITP
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Zanubrutinib
Related studies linked through entity extraction aliases.
A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia
- Status
- RECRUITING
- Phase
- PHASE2
Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE2
Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia
- Status
- RECRUITING
- Phase
- PHASE2
Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
- Status
- RECRUITING
- Phase
- PHASE2
Zanubrutinib Monotherapy in Relapsed/Refractory Central Nervous System Lymphoma
- Status
- UNKNOWN
- Phase
- NA
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
- Status
- RECRUITING
- Phase
- PHASE3
Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib
- Status
- COMPLETED
- Phase
- PHASE2
Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE2
Intravitreal MTX and ZR Regimen in Newly Diagnosed PVRL
- Status
- UNKNOWN
- Phase
- PHASE2
Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma
- Status
- SUSPENDED
- Phase
- PHASE1
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL
- Status
- UNKNOWN
- Phase
- PHASE2
Zanuburutinib in Relapsed and Refractory iMCD: a Prospective, Single-center, Single-arm Trial
- Status
- UNKNOWN
- Phase
- PHASE2
Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL
- Status
- UNKNOWN
- Phase
- PHASE2
Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma
- Status
- SUSPENDED
- Phase
- PHASE2
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Zanubrutinib in Participants With Active Proliferative Lupus Nephritis
- Status
- COMPLETED
- Phase
- PHASE2
Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies
- Status
- COMPLETED
- Phase
- PHASE1